financetom
Forex World Market Business Cryptocurrency Commodities MAP
financetom
Business
financetom
/
Business
/
Clearmind Medicine Secures Institutional Review Board Approval for CMND-100's Phase 1/2a Trial in Alcohol Use Disorder; Shares Rise Pre-Bell
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Clearmind Medicine Secures Institutional Review Board Approval for CMND-100's Phase 1/2a Trial in Alcohol Use Disorder; Shares Rise Pre-Bell
Dec 24, 2024 4:54 AM

07:21 AM EST, 12/24/2024 (MT Newswires) -- Clearmind Medicine ( CMND ) shares surged more than 84% premarket Tuesday after the company said it has received Institutional Review Board approval from Yale University for the phase 1/2a clinical trial of CMND-100 in alcohol use disorder.

The company said the approval brings it a step closer to starting the US Food and Drug Administration-regulated clinical program and further expands the multi-site trial.

According to Clearmind Medicine ( CMND ), the trial is designed to evaluate CMND-100's ability to reduce alcohol cravings and consumption among individuals with moderate to severe alcohol use disorder.

Price: 2.25, Change: +1.03, Percent Change: +84.43

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Salesforce Q2 Likely Faces 'Softening' Business Trends, Oppenheimer Says
Salesforce Q2 Likely Faces 'Softening' Business Trends, Oppenheimer Says
Aug 26, 2025
11:12 AM EDT, 08/26/2025 (MT Newswires) -- Salesforce ( CRM ) Q2 is likely faced with softening business trends with limited near-term catalysts, Oppenheimer said in a preview note Tuesday. Its fiscal Q2 results are due on Sept. 3. The report said its research mosaic, including competitor checks and company-specific data, for the quarter softened for business activity, pipeline momentum,...
 Greif Raises Quarterly Dividend for Class A, Class B Shares
Greif Raises Quarterly Dividend for Class A, Class B Shares
Aug 26, 2025
11:14 AM EDT, 08/26/2025 (MT Newswires) -- Greif ( GEF ) said Tuesday it has raised its quarterly dividend to $0.56 per class A share and $0.84 per class B share. Both dividends are payable Oct. 1 to stockholders of record as of Sept. 16, the company said. Price: 66.23, Change: -0.27, Percent Change: -0.40 ...
 Curanex Pharmaceuticals Shares Fall in Nasdaq Debut
Curanex Pharmaceuticals Shares Fall in Nasdaq Debut
Aug 26, 2025
11:09 AM EDT, 08/26/2025 (MT Newswires) -- Curanex Pharmaceuticals (CURX) shares fell in their Nasdaq debut on Tuesday after the company priced its initial public offering of 3.75 million common shares at $4 each. The stock fell 1.7% to $3.93 in recent trading after opening at $3.80. The IPO is expected to close on Wednesday. Price: 3.93, Change: -0.07, Percent...
 Emerita Resources Raises $26.1-Million in Concurrent Brokered and Non-Brokered Private Placements
Emerita Resources Raises $26.1-Million in Concurrent Brokered and Non-Brokered Private Placements
Aug 26, 2025
11:09 AM EDT, 08/26/2025 (MT Newswires) -- Emerita Resources ( EMOTF ) on Tuesday closed a brokered private placement of share units for about $25 million and its concurrent non-brokered upsized private placement of units for $1.1 million. In a private placement conducted on a best-efforts agency basis, it issued 23.8-million units at $1.05 apiece. The company issued 1.0 million...
About
Terms and Conditions Privacy policy Cookie Settings Contact Us
Services
Login register
financetom Market Personal Finance Business Economy Cryptocurrency MAP
Links
zpostcode Recruit weather mreligion Yellowpages sport constellation shopping name game directory literature Word tour furnish Lottery tftnews lyrics News digital car dir Edu Finance
Copyright 2023-2026 - www.financetom.com All Rights Reserved